Market Spotlight: Venous Thromboembolism (VTE)
Market Spotlight: Venous Thromboembolism (VTE)
$1,318.00
This Market Spotlight report covers the Venous Thromboembolism (VTE) market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Venous Thromboembolism (VTE) market, comprising key marketed and pipeline drugs, clinical trials, regulatory events, recent events and analyst opinion, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were approximately 2.4 million incident cases of deep vein thrombosis (DVT) and 1.2 million incident cases of pulmonary embolism (PE) worldwide, and forecasts that these numbers will increase to 2.7 million incident cases of DVT and 1.4 million incident cases of PE by 2030.
- Approved drugs in the venous thromboembolism (VTE) space focus on a wide variety of targets. These drugs are commonly administered via the subcutaneous route, with some products being available in oral and intravenous formulations.
- The greatest proportion of industry-sponsored drugs in active clinical development for VTE are in Phase II, with one drug in Phase III.
- Therapies in active clinical development for VTE target coagulation factor XI and carboxypeptidase U (CPU)/thrombin-activable fibrinolysis inhibitor (TAFI). These drugs are administered via intravenous, oral, subcutaneous, and topical formulations.
- The overall likelihood of approval of a Phase I VTE asset is 12.9%, and the average probability a drug advances from Phase III is 70%. Drugs, on average, take 11.0 years from Phase I to approval, compared to 9.9 years in the overall hematology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for VTE have been in the late phases of development, with 72% of trials in Phase III–IV, and 28% in Phase I–II.
- The US has a slight lead in the number of VTE clinical trials globally, while Germany leads the major European markets. Clinical trial activity in the VTE space is dominated by completed trials. Bayer has the highest number of completed clinical trials for VTE, with 40 trials.
- Bayer leads the industry sponsors with the highest overall number of clinical trials for VTE
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
7 Disease definition
7 Symptoms
7 Risk factors
8 Diagnosis
8 Patient segmentation
9 TREATMENT
9 Anticoagulants
9 Thrombolytic therapy
10 Inferior vena cava filter
10 Thrombectomy/embolectomy
11 EPIDEMIOLOGY
18 MARKETED DRUGS
22 PIPELINE DRUGS
26 RECENT EVENTS AND ANALYST OPINION
26 Milvexian for VTE (November 15, 2021)
28 MAA868 for VTE (July 19, 2021)
31 KEY REGULATORY EVENTS
31 British Columbia Adds Three Anti-Clotting Biosimilars To PharmaCare
32 PROBABILITY OF SUCCESS
33 REVENUE OPPORTUNITY
35 CLINICAL TRIAL LANDSCAPE
36 Sponsors by status
37 Sponsors by phase
38 Recent events
40 BIBLIOGRAPHY
41 APPENDIX
LIST OF FIGURES
14 Figure 1: Trends in incident cases of DVT, 2021–30
17 Figure 2: Trends in incident cases of PE, 2021–30
22 Figure 3: Overview of pipeline drugs for VTE in the US
22 Figure 4: Pipeline drugs for VTE, by company
23 Figure 5: Pipeline drugs for VTE, by drug type
23 Figure 6: Pipeline drugs for VTE, by classification
28 Figure 7: Milvexian for VTE (November 15, 2021): Phase II – AXIOMATIC-TKR
30 Figure 8: MAA868 for VTE (July 19, 2021): Phase II – ANT-005
32 Figure 9: Probability of success in the VTE pipeline
35 Figure 10: Clinical trials in VTE
35 Figure 11: Top 10 drugs for clinical trials in VTE
36 Figure 12: Top 10 companies for clinical trials in VTE
36 Figure 13: Trial locations in VTE
37 Figure 14: VTE trials status
38 Figure 15: VTE trials sponsors, by phase
LIST OF TABLES
12 Table 1: Incident cases of DVT, 2021–30
15 Table 2: Incident cases of PE, 2021–30
19 Table 3: Marketed drugs for VTE
24 Table 4: Pipeline drugs for VTE in the US
26 Table 5: Milvexian for VTE (November 15, 2021)
28 Table 6: MAA868 for VTE (July 19, 2021)
33 Table 7: Historical global sales, by drug ($m), 2017–21
34 Table 8: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Primary Sclerosing Cholangitis (PSC) 
Sign up to the